A phase II study of adding the multikinase sorafenib to existing endocrine therapy in patients with metastatic ER-positive breast cancer.

ABSTRACT: Growth factor signaling and angiogenesis may promote endocrine-resistance in breast cancer and blocking these pathways can overcome resistance in preclinical models. We conducted a phase-II study of adding the VEGFR/Ras/Raf/MAPK inhibitor sorafenib to endocrine therapy in metastatic ER-positive breast cancer, either upon progression or after maximal response with measurable residual disease. Tumor biopsies and serum were collected on days 1 and 28. Primary endpoint was response by RECIST after 3 months and secondary endpoints included safety, time to progression (TTP), and biomarker assessment. Planned sample size was 43 patients but the study closed after 11 patients because of slow accrual. 8 patients had progressive disease (PD) on entry and 3 had stable disease (SD). One patient with

ORGANISM(S): Homo sapiens

SUBMITTER: Suleiman Massarweh 

PROVIDER: E-GEOD-40837 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress